Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Blinded, Randomized, Phase 2 Study of XPro1595 to Investigate the Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-Related Deficits in Reward Circuitry and Motivation in Depression

Next Previous
X
Search
Trial Profile

A Multicenter, Blinded, Randomized, Phase 2 Study of XPro1595 to Investigate the Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-Related Deficits in Reward Circuitry and Motivation in Depression

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegipanermin (Primary)
  • Indications Depression
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Sponsors INmune Bio

    • Most Recent Events

    • 02 Aug 2024 According to an INmune Bio media release, the trial expected to initiate by 2H 2024
    • 05 May 2022 According to an INmune Bio media release, this trial will be funded in part by a $2.9 million NIH grant, by 2H 2022.
    • 03 Mar 2022 According to an INmune Bio media release, the company expects to initiate this trial by 2 H 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top